NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cheetah Mobile Inc. ("Cheetah" or the "Company") (NYSE:CMCM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cheetah securities between March 25, 2019 and February 20, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/cmcm.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) certain of Cheetah Mobile's apps were not compliant with the terms of its agreements with Google; (2) as a result, there was a reasonable likelihood that Google would terminate its advertising contracts with the Company; (3) as a result of the foregoing, the Company's ability to attract new users would be adversely impacted; (4) as a result, the Company's revenue was reasonably likely to decline; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/cmcm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Cheetah you have until August 24, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 595511

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ideanomics, Inc.

("IDEX" or the "Company") (NASDAQ:IDEX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Ideanomics securities between March 20, 2020 and June 25, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/idex.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Ideanomics' MEG Center in Qingdao was not "a one million square foot EV expo center"; (2) the Company had been using doctored or altered photographs of the purported MEG Center in Qingdao; (3) the Company's electric vehicle business in China was not performing nearly as strong as Ideanomics had represented; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class-action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/idex, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ideanomics, you have until August 27, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 595613

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Sonic Automotive, Inc. ("Sonic" or "the Company") (NYSE:SAH) for possible breaches of fiduciary duty.

Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sah. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 595509

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Enphase Energy, Inc. ("Enphase" or "the Company") (NASDAQ:ENPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Enphase securities between February 26, 2019 and June 17, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/enph.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/enph or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Enphase you have until August 17, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 595485

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Casper Sleep Inc. ("Casper" or the Company") (NYSE:CSPR) pursuant and/or traceable to the Company's initial public offering conducted on or about February 7, 2020 (the "IPO" or "Offering"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/cspr.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The complaint alleges that the Offering Materials issued connected to the Company's IPO were materially false and/or misleading and/or omitted or misrepresented the following facts: (1) Casper's profit margins were actually declining, rather than growing; (2) Casper was changing an important distribution partner, costing it 130 basis points of gross margin in the first quarter of 2020 alone; (3) Casper was holding a glut of old and outdated mattress inventory that it was selling at steeply discounted clearance prices, further impairing the Company's profitability; (4) Casper was suffering accelerating losses, further placing its ability to achieve positive cash flows and profitability out of reach; (5) Casper's core operations were not profitable, but were causing the Company to suffer over $40 million in negative cash flows during the first quarter of 2020 alone and doubling its quarterly net loss year over year; (6) as a result of the foregoing, Casper's ability to achieve profitability, implement its growth initiatives, and expand internationally had been misrepresented in the Offering Documents, as the Company needed to shutter its European operations, halt all international expansion, jettison over one fifth of its global corporate workforce, and significantly curtail new store openings in order to avoid an imminent cash and liquidity crisis, let alone achieve positive operating cash flows; and (7) as a result of the foregoing, Casper's revenue growth rate was not sustainable and had not positioned the Company to achieve profitability.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/cspr or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Casper you have until August 18, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 595481

FLORHAM PARK, NJ / ACCESSWIRE / June 29, 2020 / Hisamitsu America, the marketers of Salonpas®, announce today that The Journal of Pain Research, an international, peer-reviewed scientific journal focusing on pain research and the prevention and management of pain, features the publication, in June 2020, of the RELIEF study: "Relieving Pain: Evaluating Patient Quality of Life Improvement – Perceptions, Experience and Feedback After Use of a Topical Pain Relief Patch," an exploratory pain management study, conducted by Clarity Science.

The comprehensive Institutional Review Board (IRB)-approved study evaluated whether a topical analgesic pain-relieving patch containing methyl salicylate (10%), Menthol (6%) and Camphor (3.1%) could reduce pain severity and improve function in patients with mild-to-moderate arthritic, neurological or musculoskeletal pain as compared to oral over-the-counter (OTC) agents (e.g., ibuprofen, naproxen, acetaminophen, and other pain medications such as creams, gels, roll-ons, sprays, patches or rubs, prescription NSAIDs (e.g., ibuprofen, naproxen, celecoxib, meloxicam or diclofenac), prescription opioids (e.g., fentanyl, hydrocodone, hydromorphone, morphine or oxycodone), or prescription anticonvulsants (e.g., gabapentin or pregabalin).

The treatment group for the RELIEF study included 152 adult patients with arthritis, neurological, or musculoskeletal pain who received the Salonpas® Pain Relieving Patch for 14 days. A control group included 47 patients who did not receive the patch – 34 of whom crossed over to evaluate their response to patch treatment as well.

Pain severity in treated patients decreased significantly, by 49.0% compared to 12.3% in patients in the control group, while function significantly improved by 58.1% compared to 14.8% in patients in the control group. Additionally, no side effects of treatment were reported. Also, at day 14, 60.5% of the treated patients were using concomitant oral pain medications a lot less and 90.8% of patients were very or extremely satisfied with the patch. Patients in the crossover group showed similar reductions in pain severity and improvement in function.

"Clinical treatment guidelines increasingly recommend the first-line use of topical analgesics, largely based on safety concerns associated with oral medications such as oral NSAIDs, acetaminophen, opioids, and anticonvulsants, which require substantial systemic exposure in order to have their therapeutic effect and pose associated risk of serious adverse events," said Dr. Jeffrey Gudin, the Principal Investigator of the RELIEF study who is board certified in pain management, anesthesiology, addiction medicine and palliative care. Dr. Gudin is affiliated with Englewood Hospital Medical Center and Rutgers New Jersey Medical School, Dept. of Anesthesiology, and is an author, researcher and opinion leader in pain management. "The RELIEF study not only supported the safety of this multimodal topical analgesic (Salonpas Pain Relieving Patch), it also supported the treatment's significant pain relieving effect in patients with mild to moderate pain, its favorable impact on function, and illustrated that its use reduced the use of oral NSAIDs, acetaminophen, opioids, and anticonvulsants."

"Our mission is to provide people in pain with clinically proven topical analgesics and practitioners with the clinical proof they need to confidently recommend our products for their patients," said John Incledon, the President of Hisamitsu America Inc. "Prior to the RELIEF study, Hisamitsu supported the clinical evaluation of another one of it products, the Salonpas® Pain Relief Patch LARGE. The study was a well-controlled clinical study involving 208 patients with mild to moderate pain. Patients treated with the product experienced significantly more pain relief versus patients treated with a placebo patch and the majority of patients rated satisfaction with the product as good, very good, or excellent. This study ultimately supported an FDA approval of a New Drug Application for the product, making it not only the first FDA approved OTC topical analgesic, but also the only OTC pain reliever, systemic or topical, that is approved to treat mild and moderate pain. We will continue to provide people in pain and health care practitioners with clinical proof of the efficacy and safety of our products, so stay tuned for more news to come."

Oral pain relievers, mainly opioids, NSAIDs and acetaminophen are leading causes of serious adverse events (SAE's); addiction, hospitalization for CV & GI risk, liver toxicity, and death. The Center for Disease Control (CDC) reports that since 2000, over 200,000 people in the USA have died from overdose of prescription opioids. In 2016, the CDC issued guidance to physicians managing chronic pain without opioids, that topical analgesics can be an alternative first line therapy.

Based in Narragansett, Rhode Island, Clarity Science, LLC conducts scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide.

Hisamitsu America provided a grant to Clarity Science to administer and conduct the IRB-approved study to collect data on patient outcomes for Quality of Life (QoL) components, pain relief scores and assessment of severity of pain and its impact on functioning, patient satisfaction, and an evaluation of differences, reported medical conditions and other prescribed or OTC oral medications commonly associated with pain.

About Hisamitsu America:

Hisamitsu America is the US division of Hisamitsu Pharmaceutical Co., Inc., founded in 1847, which has specialized in transdermal drug delivery system technology since the introduction of its Salonpas line of patches in 1934. The Salonpas® product line, which gained early acceptance in Asia and is now registered in over 30 countries, has pioneered the development of transdermal patches to relieve pain. Since 2010, Salonpas has become one of the fastest growing OTC brands in the USA. The Salonpas Pain Relief Patch LARGE holds the distinction of being the first topical analgesic approved OTC by the FDA and the only one to be approved for the treatment of mild to moderate pain. Salonpas became the most popular pain relief brand on Facebook in 2020. For more information, https://us.hisamitsu/.

# # #

Media Contact:

Nancy Thompson, Vorticom, Inc.
212.532.2208 (o)
917-371-4053 (m)
nancyt@vorticom.com

SOURCE: Hisamitsu America

ReleaseID: 595344